Small vessel stroke and white matter lesions
Peas in a pod, or horses of a different color?
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Damage to small penetrating vessels is an important unifying cause of ischemic and hemorrhagic strokes. Both types of stroke involve tiny arterioles and are often pathologic twins, arteriolosclerosis and lipohyalinosis being the predominant underlying causes.1 Another entity increasingly linked to small vessel damage is extensive leukoaraiosis: white matter lesions frequently seen on T2-weighted magnetic resonance scans of older people. In this issue of Neurology®, Rost et al.2 report hospital-based findings from 3 stroke registries showing a greater burden of leukoaraiosis in participants with small vessel stroke (including both ischemic and hemorrhagic forms) compared to other ischemic stroke subtypes, supporting a link among these 3 entities.
Thought of together, as peas in a pod, ischemic and hemorrhagic small vessel damage accounts for about one-third of all strokes and represents an important cause of morbidity and mortality. Ischemic small vessel stroke, often referred to as “lacunar,” is usually manifested as infarctions less than 1.5 cm in diameter on CT or MRI, and attributed to thrombosis of a penetrating vessel in the basal ganglia, thalamus, deep white matter, or brainstem. Studies suggest that lacunar strokes are associated with lower short-term disability and mortality than other ischemic stroke subtypes, and reported 1-year case-fatality rates are low, near 3%. …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
White matter hyperintensity volume is increased in small vessel stroke subtypesN.S. Rost, R.M. Rahman, A. Biffi et al.Neurology, November 08, 2010 -
Article
Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypesMarios K. Georgakis, Dipender Gill, Alastair J.S. Webb et al.Neurology, July 01, 2020 -
Abstracts
Proceedings of the 25th International Stroke Genetics Consortium Workshop: Cambridge, UKJemma C. Hopewell, Matthew Traylor, Hugh S. Markus et al.Neurology: Genetics, May 21, 2020 -
Article
Diabetes Mellitus, Glycemic Traits, and Cerebrovascular DiseaseA Mendelian Randomization StudyMarios K. Georgakis, Eric L. Harshfield, Rainer Malik et al.Neurology, January 25, 2021